Literature DB >> 8481915

p53 mutation is a common genetic event in ovarian carcinoma.

B J Milner1, L A Allan, D M Eccles, H C Kitchener, R C Leonard, K F Kelly, D E Parkin, N E Haites.   

Abstract

Using the single-strand conformational polymorphism technique, we have screened 66 malignant ovarian tumors for p53 mutation in exons 5 to 8. Thirty-four of the tumors demonstrated a single-strand conformational polymorphism band shift in this region of the gene, including 6 in exon 5, 7 in exon 6, 12 in exon 7, and 10 in exon 8 (one of the tumors showed a shift for exons 7 and 8). All of the single-strand conformational polymorphism shifts have been further characterized by DNA sequencing, and 31 of 35 have been shown to represent genuine DNA alterations. These include 27 point mutations (23 missense, 2 nonsense, and 2 silent mutations), 3 deletions (a 2-base pair deletion introducing, by frameshift, a stop codon further downstream; a 3-base pair deletion; and an unusual 6-base pair deletion made up of separate 2-base pair and 4-base pair deletions), and a 4-base pair insertion (introducing a stop codon downstream). In total, 29 of the 66 (44%) carcinomas analyzed had mutations affecting the primary sequence of the p53 protein. p53 mutation was found in tumors of all International Federation of Gynecologists and Obstetricians stages, suggesting that it might be an earlier genetic event in the progression of epithelial ovarian tumors than previously thought. A significantly greater number of p53 mutations were seen in high-grade serous carcinomas than in those of endometrioid and mucinous types (0.02 > P > 0.01). Analysis of the distribution of point mutations showed no preference for any particular mutation type.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8481915

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Selective genetic analysis of p53 immunostain positive cells.

Authors:  M Phelps; B S Wilkins; D B Jones
Journal:  Mol Pathol       Date:  2000-06

2.  Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian carcinomas.

Authors:  R Wu; D C Connolly; X Ren; E R Fearon; K R Cho
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

3.  Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.

Authors:  A Reles; A Schmider; M F Press; I Schönborn; W Friedmann; S Huber-Schumacher; T Strohmeyer; W Lichtenegger
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC.

Authors:  H Lassus; R Salovaara; L A Aaltonen; R Butzow
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

5.  p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity.

Authors:  P Röhlke; K Milde-Langosch; C Weyland; U Pichlmeier; W Jonat; T Löning
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

6.  Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.

Authors:  Teodora A Todorova; Stanislav H Jordanov; Gergana S Stancheva; Ivan J Chalakov; Mincho B Melnicharov; Kuncho V Kunev; Vanio I Mitev; Radka P Kaneva; Teodora E Goranova
Journal:  Pathol Oncol Res       Date:  2014-08-23       Impact factor: 3.201

7.  The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.

Authors:  Zhu Yuan; Kang Cao; Chao Lin; Lei Li; Huan-yi Liu; Xin-yu Zhao; Lei Liu; Hong-xin Deng; Jiong Li; Chun-lai Nie; Yu-quan Wei
Journal:  Mol Med       Date:  2011-08-19       Impact factor: 6.354

8.  Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53.

Authors:  F Vikhanskaya; E Erba; M D'Incalci; M Broggini
Journal:  Nucleic Acids Res       Date:  1994-03-25       Impact factor: 16.971

9.  Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status.

Authors:  M Koshiyama; I Konishi; M Mandai; T Komatsu; S Yamamoto; K Nanbu; T Mori
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.

Authors:  Cheng-Han Lee; Subbaya Subramanian; Andrew H Beck; Inigo Espinosa; Janine Senz; Shirley X Zhu; David Huntsman; Matt van de Rijn; C Blake Gilks
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.